Transplant Outcomes for IgA Multiple Myeloma: Real-World Insights from the Daratumumab Era

Key Points

• Transplant outcomes improved in IgA multiple myeloma patients after daratumumab treatment, indicating enhanced survival rates.
• An overall survival rate of 72% within 24 months showcases the efficacy of daratumumab in real-world settings.
• Observational analysis across multiple centers shows strong coordination among treatment protocols and patient management strategies.
• Highlights the need for further studies in diverse populations for broader applicability of these findings.